A number of small studies have found that ketamine can do something no other drug can: it often relieves even suicidal depression in a matter of hours in patients who have not responded to other treatments.
Ketamine's potential as an antidepressant was recognized more than a decade ago. And studies done since then provide "compelling evidence that the antidepressant effects of ketamine infusion are both rapid and robust, albeit transient," according to a consensus statement from a task force of the American Psychiatric Association. Sanacora is one of the task force members.
But there are still a lot of unanswered questions about ketamine, says James Murrough, an assistant professor of psychiatry and neuroscience at the Icahn School of Medicine at Mt. Sinai in New York.
"We haven't had large-scale trials. We don't know how much or how often it should be given for it to be effective or safe," says Murrough, who is an author of a review of ketamine published in the journal Nature Reviews Drug Discovery.
Doctors know a lot about the short-term effects of ketamine because it has been used as an anesthetic in emergency rooms for decades. But there's still not much information about the effects of using ketamine for years.
That's worrisome because ketamine's antidepressant effect tends to wear off after a few days or weeks, meaning patients need repeated infusions to keep depression at bay, Murrough says.
Still, Murrough thinks the case for using ketamine is much stronger than it was just a few years ago.
"There's warranted caution that's balanced with an optimism that says we've never had a new medication for depression since the era of Prozac," Murrough says.
Prozac arrived in the 1980s, and became the first of a new class of depression drugs that target the neurotransmitter serotonin.
Ketamine acts on a different neurotransmitter called glutamate. The drug's success has pharmaceutical companies excited about the possibility of creating a whole new class of drugs for depression, Murrough says.
"Companies are reopening programs," he says. "They are pulling [old] drugs off the shelf that they know act on the glutamate system."
One promising candidate is a chemical sibling of ketamine called esketamine. It's now in the final phase of testing before consideration by the Food and Drug Administration, which designated esketamine as a breakthrough therapy.
And esketamine is just one of several ketamine-like drugs in development, says Sanacora, who consults for companies developing these drugs.